Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas

Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas

Abstract Background Surgery is a common treatment strategy for patients with neurofibromatosis type 1 (NF1)-related plexiform neurofibroma (PN) and has limited efficacy. FCN-159 is a novel anti-tumorigenic drug via selective inhibition of MEK1/2. This study assesses the safety and efficacy of FCN-15...

Full description

Bibliographic Details
Main Authors: Xiaojie Hu, Wenbin Li, Kang Zeng, Zhongyuan Xu, Changxing Li, Zhuang Kang, Shenglan Li, Xin Huang, Pu Han, Hongmei Lin, Ai-Min Hui, Yan Tan, Lei Diao, Ben Li, Xingli Wang, Zhuli Wu, Xiaoxi Lin
Format: Article
Language:English
Published: BMC 2023-07-01
Series:BMC Medicine
Subjects:
Neurofibromatosis-1
FCN-159
MEK1/2 inhibition
Online Access:https://doi.org/10.1186/s12916-023-02927-2

Internet

https://doi.org/10.1186/s12916-023-02927-2

Similar Items